Q2 FY2026 EarningsQ2 FY26 results slightly missed consensus on the bottom line, reporting a GAAP EPS of -$0.69 vs. -$0.63 expected. Revenue remains at $0 as expected for a clinical-stage biotech. The company reported improved R&D efficiency with expenses of $4.0M (lower than prior year), but cash reserves of $15.8M suggest a limited runway unless additional funding is secured for the newly announced TTI-109 Ulcerative Colitis (UC) clinical trials. Management highlighted positive Phase 1 data for TTI-109 and set key HCC data readouts for Q4 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Tvardi Therapeutics(TVRD) the EBIT is -6.629 M (+25.26%), Beat estimate;the EPS is -0.69 (-235.3%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.01B25.26%
-0.01B23.36%
+0.00B1.90%
EPSMiss expectations
-0.69235.29%
-0.625222.55%
-0.065012.74%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf